MedTrace Logo

Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali

NCT01487278 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-01-09

No results posted yet for this study

Summary

This is a large, community-based, cluster-randomized trial to compare routine prophylactic use of 600 mcg oral misoprostol and 10 IU oxytocin delivered by UnijectTM intramuscularly during the third stage of labor.

Conditions

  • Postpartum Hemorrhage

Interventions

DRUG

misprostol

600 mcg misoprostol oral

DEVICE

UnijectTM

10 IU oxytocin delivered intramuscularly with UnijectTM

Sponsors & Collaborators

  • The Aga Khan Foundation

    collaborator OTHER

  • Guttmacher Institute

    collaborator OTHER

  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Ayisha R Diop, MPH · Gynuity Health Projects

  • Laura J Frye, MPH · Gynuity Health Projects

  • Yacouba Kone, M.D · The Aga Khan Foundation

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • Mali

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01487278 on ClinicalTrials.gov